(Q84104357)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

phase I clinical trial

1 reference

1 reference

Olga Pleguezuelos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Stuart Robinson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Gregory A Stoloff

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Wilson Caparrós-Wanderley

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

8 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

4655-4660

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

French economic evaluations of influenza and influenza vaccination

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

1918 Influenza: the mother of all pandemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

The annual production cycle for influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Influenza vaccines for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Immune responses to influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Multiple sequence alignment with the Clustal series of programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

"Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Pre-pandemic and pandemic influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Influenza vaccine immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Immune response to influenza vaccination in a large healthy elderly population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Influenza control in the 21st century: Optimizing protection of older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Declining T-cell immunity to influenza, 1977-82

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

Cell-mediated protection in influenza infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.089

10.1016/J.VACCINE.2012.04.089

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22575166%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference